

Statewide Commercial Performance on the ACO Core Measure Set

Rhode Island scored above the national 75th percentile for the commercial market on all measures for which national benchmarks were available, except one – *Glycemic Status Assessment for Patients with Diabetes* – for which performance was below that benchmark. Rhode Island exceeded the national 90th percentile on all but three of the measures, *Controlling High Blood Pressure*, *Glycemic Status Assessment*, and *Follow-Up After Hospitalization for Mental Illness (7-Day)* (see Table 5.1).⁷ Commercial performance on *Controlling High Blood Pressure* has been stagnant at 74% for the past three years (2022–2024), while performance on *Glycemic Status Assessment* and *Follow-Up After Hospitalization for Mental Illness (7-Day)* has improved (from 63 percent to 67 percent and from 58 percent to 59 percent, respectively), with the latter measure’s improvement likely not statistically significant.

Table 5.1: 2024 Statewide Commercial Performance on the ACO Core Measure Set

Measure	National Benchmarks		Statewide Performance	
	75TH PERCENTILE	90TH PERCENTILE	ABOVE 75TH PERCENTILE?	ABOVE 90TH PERCENTILE?
Breast Cancer Screening	77%	80%	Yes 86%	Yes 86%
Child and Adolescent Well-Care Visits (Total)	66%	74%	Yes 79%	Yes 79%
Chlamydia Screening	49%	57%	Yes 66%	Yes 66%
Colorectal Cancer Screening	63%	68%	Yes 76%	Yes 76%
Controlling High Blood Pressure	71%	75%	Yes 74%	No 74%
Eye Exam for Patients with Diabetes	55%	61%	Yes 68%	Yes 68%
Follow-Up After Hospitalization for Mental Illness (7-Day)	56%	64%	Yes 59%	No 59%
Glycemic Status <8.0%	69%	73%	No 67%	No 67%
Immunizations for Adolescents (Combo 2)	36%	41%	Yes 60%	Yes 60%
Lead Screening in Children	NA	NA	87%	87%

Source: OHIC analysis of quality performance data submitted by commercial insurers in Rhode Island. Statewide commercial performance is based on a weighted average of insurer performance using membership from the insurers’ cost growth target data submissions, rather than performance for the full population, because multiple insurers submitted measurement data using population samples.

Statewide Medicaid Performance on the ACO Core Measure Set

In 2024, Rhode Island exceeded the national 75th percentile for the Medicaid market on all but three measures – *Chlamydia Screening in Women*, *Controlling High Blood Pressure*, and *Glycemic Status Assessment for Patients with Diabetes*. Rhode Island did not exceed the national 90th percentile on any of the measures, despite seeing slightly higher performance rates for almost all measures compared to the prior year. This is a dramatic departure from 2023, when Rhode Island exceeded the national 90th percentile on all but four measures in the ACO Core Measure Set. In general, Medicaid managed care quality performance across the U.S. has improved at a greater rate than in Rhode Island.

⁷ National benchmarks were not available for the commercial market for *Lead Screening in Children*.

Table 5.2. 2024 Statewide Medicaid Performance on the ACO Core Measure Set

Measure	National Benchmarks		Statewide Performance	
	75TH PERCENTILE	90TH PERCENTILE	ABOVE 75TH PERCENTILE?	ABOVE 90TH PERCENTILE?
Breast Cancer Screening	61%	66%	Yes 64%	No 64%
Child and Adolescent Well-Care Visits (Total)	61%	68%	Yes 64%	No 64%
Chlamydia Screening	65%	71%	No 64%	No 64%
Colorectal Cancer Screening	48%	53%	Yes 51%	No 51%
Controlling High Blood Pressure	71%	75%	No 71.2%	No 71%
Eye Exam for Patients with Diabetes	63%	69%	Yes 67%	No 67%
Follow-Up After Hospitalization for Mental Illness (7-Day)	49%	58%	Yes 53%	No 53%
Glycemic Status <8.0%	65%	67%	No 59%	No 59%
Immunizations for Adolescents (Combo 2)	44%	52%	Yes 46%	No 46%
Lead Screening in Children	76%	83%	Yes 79%	No 79%

Source: OHIC analysis of quality performance data of Rhode Island Medicaid managed care organizations obtained from EOHHS. Medicaid performance represents the full population for the measure because EOHHS requires that insurers submit performance data for their full population.

Tables 5.1 and 5.2 demonstrate significant inequities in quality between commercial and Medicaid populations for some measures, with much smaller gaps for others. Notable opportunities for improved health equity for Medicaid members exist for Breast Cancer Screening (22 percentage-point difference), Child and Adolescent Well-Care Visits and Colorectal Cancer Screening (15 percentage-point difference each) and Immunizations for Adolescents (Combo 2) (14 percentage-point difference).

Longitudinal Quality Performance in the Commercial Market

In addition to assessing 2024 commercial performance on the ACO Core Measure Set, OHIC analyzed longitudinal performance for measures that are in the ACO Measure Set from 2011 to 2024. Of the six measures that are in the ACO Measure Set, two saw improved performance and four saw a decline in performance between 2011 and 2024 (see Table 5.3). This lack of meaningful performance improvement is troubling. Similar patterns of lack of performance improvement for these measures are seen for neighboring states of Connecticut and Massachusetts. Only one of the six measures saw a decline in performance nationally during this time period.

We cannot say with certainty what contributed to this performance deterioration. OHIC analysis found that it cannot be explained by a decline in access to well-care visits, but the lack of *increased* well-care utilization may have been a barrier to improvement. Substantial declines in performance for *Controlling High Blood Pressure*, *Follow-Up After Hospitalization for Mental Illness (7-Day)*, and *Glycemic Status (<8%)* warrant attention. Lack of control of blood pressure and blood sugar are each associated with higher morbidity and mortality.

Table 5.3: Cumulative Change in Commercial Performance (2011–2024)

Measure	Rhode Island	Connecticut	Massachusetts	National
Breast Cancer Screening	+1.2%	+5.3%	+/- 0%	+6.3%
Chlamydia Screening	+14.0%	-3.2%	+2.9%	+3.3%
Colorectal Cancer Screening	-2.1%	+/- 0%	-7.9%	+0.7%
Controlling High Blood Pressure	-5.9%	+3.1%	-2.3%	+1.9%
Follow-up After Hospitalization for Mental Illness (7-Day)	-16.0%	-7.8%	-18.4%	-6.1%
Glycemic Status <8.0%	-8.6%	+1.7%	-3.1%	+5.1%

Source: NCQA Quality Compass.

Insurers’ Performance on the ACO Core Measure Set

Commercial Insurers’ Performance on the ACO Core Measure Set

OHIC collects performance for four commercial insurers (BCBSRI, NHPRI, THP, and UHC). This report presents performance for all the insurers except for THP because THP did not have denominators large enough to report for the preponderance of measures. Overall, the insurers performed well on adult prevention and screening and pediatric care measures, including *Breast Cancer Screening*, *Chlamydia Screening*, *Colorectal Cancer Screening*, *Immunizations for Adolescents (Combo 2)*, *Eye Exam for Patients with Diabetes*, and *Child and Adolescent Well-Care Visits (Total)*, with more mixed results on chronic disease management and behavioral health measures.

- BCBSRI exceeded the national 75th percentile for nearly all reported measures and frequently achieved performance at or above the 90th percentile, except for *Controlling High Blood Pressure*, *Follow-Up After Hospitalization for Mental Illness (7-Day)*, and *Glycemic Status <8.0%*.
- UHC met or exceeded the 75th percentile on several preventive measures, including *Breast Cancer Screening*, *Chlamydia Screening*, *Immunizations for Adolescents (Combo 2)*, and *Eye Exam for Patients with Diabetes*, but did not consistently reach top-percentile benchmarks for *Child and Adolescent Well-Care Visits (Total)*, *Colorectal Cancer Screening*, *Controlling High Blood Pressure*, or *Glycemic Status <8.0%*.
- NHPRI exceeded the 75th percentile on select screening and immunization measures but did not achieve this benchmark on several chronic disease and follow-up measures, including *Follow-Up After Hospitalization for Mental Illness (7-Day)* and *Glycemic Status <8.0%*. Across insurers, performance was strongest for cancer screening, immunizations, and diabetes eye exams, and weakest for glycemic control and follow-up after hospitalization for mental illness.

BCBSRI’s performance compared favorably to the other insurers across most measures, while NHPRI’s overall performance compared unfavorably to that of BCBSRI and UHC. (see Table 5.4).

Table 5.4: 2024 Commercial Insurers' Performance on the ACO Core Measure Set

Measure Name	National Benchmarks		Above 75th Percentile?			Above 90th Percentile?		
	75TH PCTL	90TH PCTL	BCBSRI	NHPRI	UHC	BCBSRI	NHPRI	UHC
% of Measures Above Nat'l Benchmark			100%	44%	89%	67%	44%	56%
Breast Cancer Screening	77%	80%	Yes 88%	No 76.9%	Yes 80%	Yes 88%	No 77%	Yes 80.2%
Child and Adolescent Well-Care Visits (Total)	66%	74%	Yes 83%	No 59%	Yes 74%	Yes 83%	No 59%	No 73.8%
Chlamydia Screening	49%	57%	Yes 67%	Yes 60%	Yes 65%	Yes 67%	Yes 60%	Yes 65%
Colorectal Cancer Screening	63%	68%	Yes 81%	No 60%	Yes 66%	Yes 81%	No 60%	No 66%
Controlling High Blood Pressure	71%	75%	Yes 75%	Yes 78%	Yes 71.3%	No 74.8%	Yes 78%	No 71%
Eye Exam for Patients with Diabetes	55%	61%	Yes 71%	Yes 70%	Yes 62%	Yes 71%	Yes 70%	Yes 62%
Follow-Up After Hospitalization for Mental Illness (7-Day)	56%	64%	Yes 58%	No 51%	Yes 66%	No 58%	No 51%	Yes 66%
Glycemic Status <8.0%	69%	73%	Yes 70%	No 23%	No 68%	No 70%	No 23%	No 68%
Immunizations for Adolescents (Combo 2)	36%	41%	Yes 60%	Yes 46%	Yes 54%	Yes 60%	Yes 46%	Yes 54%
Lead Screening in Children	NA	NA	86%	NA	NA	86%	NA	NA

Source: OHIC analysis of quality performance data submitted by commercial insurers in Rhode Island.

Notes:

NA = Not Available. Insurer did not submit performance on this measure.

NR = Not Reported. The insurer did not meet the minimum denominator size required for public reporting.

Medicaid Insurers' Performance on the ACO Core Measure Set

OHIC reports performance for two Medicaid plans (NHPRI and UHCCP).⁸ Overall, plan performance was mixed and generally below national top-percentile benchmarks, with more limited attainment of the 75th and 90th percentiles than observed in the commercial market. Both plans exceeded the national 75th percentile for several measures, including *Breast Cancer Screening*, *Child and Adolescent Well-Care Visits (Total)*, *Colorectal Cancer Screening*, *Immunizations for Adolescents (Combo 2)*, *Lead Screening in Children*, and *Follow-Up After Hospitalization for Mental Illness (7-Day)*, though neither plan consistently achieved 90th percentile performance.

NHPRI and UHC performance was comparable for nearly all measures. NHPRI exceeded the 75th percentile for *Eye Exam for Patients with Diabetes*, while UHCCP exceeded this benchmark for *Controlling High Blood Pressure* and *Follow-Up After Hospitalization for Mental Illness (7-Day)*. Both plans performed below 75th percentile national benchmarks for *Chlamydia Screening* and *Glycemic Status <8.0%*.

Across measures, performance was strongest for pediatric and preventive services and weakest for chronic disease management, particularly glycemic control (see Table 5.5).

⁸ EOHHS does not collect quality data from THP due to its small enrolled population.

Table 5.5: 2024 Medicaid Insurers’ Performance on ACO Core Measure Set

Measure	National Benchmarks		Above 75th Percentile?		Above 90th Percentile?	
	75TH PCTL	90TH PCTL	NHPRI	UHCCP	NHPRI	UHCCP
% of Measures Above Nat’l Benchmark			70%	70%	10%	10%
Breast Cancer Screening	61%	66%	Yes 65%	Yes 62%	No 65%	No 62%
Child and Adolescent Well-Care Visits (Total)	61%	68%	Yes 64%	Yes 65%	No 64%	No 65%
Chlamydia Screening	65%	71%	No 64%	No 64%	No 64%	No 64%
Colorectal Cancer Screening	48%	53%	Yes 52%	Yes 50%	No 52%	No 50%
Controlling High Blood Pressure	71%	75%	No 70%	Yes 73%	No 70%	No 73%
Eye Exam for Patients with Diabetes	63%	69%	Yes 70%	No 61%	Yes 70%	No 61%
Follow-Up After Hospitalization for Mental Illness (7-Day)	49%	58%	Yes 51%	Yes 58%	No 51%	Yes 57.9%
Glycemic Status <8.0%	65%	67%	No 59%	No 60%	No 59%	No 60%
Immunizations for Adolescents (Combo 2)	44%	52%	Yes 45%	Yes 49%	No 45%	No 49%
Lead Screening in Children	76%	83%	Yes 80%	Yes 77%	No 80%	No 77%

Source: OHIC analysis of quality performance data submitted by Rhode Island managed care plans to EOHS and provided to OHIC by EOHS.

Providers’ Performance on the ACO Core Measure Set

OHIC reports on quality performance of the state’s ACOs and AEs. This is different from the large provider entity reporting for cost growth. OHIC maintains the ACO and AE construct for quality reporting to align with payers’ contractual arrangements with these organizations.

ACO Commercial Performance on the ACO Core Measure Set – 75th Percentile

There was notable variation in 2024 ACO commercial performance on the ACO Core Measure Set relative to the national 75th percentile.

- Brown University Health, Integra, and Prospect (now Astrana Health) performed strongest overall, exceeding the 75th percentile on nearly all measures with sufficient denominator size, including *Breast Cancer Screening*, *Child and Adolescent Well-Care Visits (Total)*, *Colorectal Cancer Screening*, *Controlling High Blood Pressure*, *Eye Exam for Patients with Diabetes*, and *Glycemic Status <8.0%*.
- Thundermist and IHP exceeded the 75th percentile on a majority of measures but did not consistently achieve this benchmark across all chronic disease measures.
- PCHC and BVCHC exceeded the 75th percentile on few measures, with BVCHC not meeting that benchmark for any measure with sufficient denominator size.

Overall, non-Federally Qualified Health Center (FQHC)-based provider organizations demonstrated superior performance to that of FQHCs. FQHCs are federally funded nonprofit health centers or clinics that serve medically underserved areas and populations. OHIC cannot determine if this difference reflects a) better care, b) better quality measurement or improvement processes, and/or c) differences in the social and health risks of patient populations.

Across ACOs, performance was strongest for preventive and screening measures, including *Chlamydia Screening* and *Immunizations for Adolescents (Combo 2)*, and more variable for *Controlling High Blood Pressure* and *Glycemic Status <8.0%*. Smaller denominator sizes limited reporting for *Follow-Up After Hospitalization for Mental Illness (7-Day)* and *Lead Screening in Children* for several ACOs (see Table 5.6).

Table 5.6: 2024 ACO Commercial Performance on the ACO Core Measure Set – 75th Percentile

Measure Name	Nat'l 75th Pctl	Above 75th Percentile?						
		BVCHC	BROWN	INTEGRA	IHP	PCHC	PROSPECT	THUNDER-MIST
% of Measures Above Nat'l Benchmark		0%	100%	100%	67%	38%	88%	63%
Breast Cancer Screening	77%	No 68%	Yes 91%	Yes 89%	No 76.6%	No 71%	Yes 86%	No 76%
Child and Adolescent Well-Care Visits (Total)	66%	No 56%	Yes 83%	Yes 85%	Yes 73%	No 65.8%	Yes 73%	Yes 75%
Chlamydia Screening	49%	NR	Yes 73%	Yes 66%	Yes 51%	Yes 66%	Yes 63%	Yes 57%
Colorectal Cancer Screening	63%	No 55%	Yes 85%	Yes 81%	Yes 69%	No 53%	Yes 81%	Yes 66%
Controlling High Blood Pressure	71%	No 54%	Yes 74%	Yes 79%	Yes 73%	No 67%	Yes 83%	No 67%
Eye Exam for Patients with Diabetes	55%	No 35%	Yes 75%	Yes 65%	Yes 62%	Yes 59%	Yes 74%	Yes 68%
Follow-Up After Hospitalization for Mental Illness (7-Day)	56%	NR	Yes 63%	Yes 56.1%	No 47%	NR	No 55%	NR
Glycemic Status <8.0%	69%	No 37%	Yes 74%	Yes 70%	No 44%	No 58%	Yes 72%	No 59%
Immunizations for Adolescents (Combo 2)	36%	NR	Yes 64%	Yes 63%	Yes 45%	Yes 41%	NR	Yes 63%
Lead Screening in Children	NA	NR	85%	84%	NR	NR	NR	NR

Source: OHIC analysis of quality performance data submitted by commercial insurers in Rhode Island.

Note:

NA = Not Available.

NR = Not Reported. The ACO/AE did not meet the minimum denominator size required for public reporting.

ACO Commercial Performance on the ACO Core Measure Set – 90th Percentile

There was greater variation in ACO performance relative to the national 90th percentile.

- Brown University Health and Integra performed strongest overall, each exceeding the 90th percentile for a majority of measures with sufficient denominator size. Prospect also exceeded the 90th percentile on several measures.
- IHP and Thundermist achieved 90th percentile performance on a more limited number of measures.
- PCHC exceeded the 90th percentile for select measures.
- BVCHC did not exceed the 90th percentile for any measures with sufficient denominator size.

No ACO exceeded the 90th percentile for *Follow-Up After Hospitalization for Mental Illness (7-Day)* and only Brown University Health did so for *Glycemic Status <8.0%* (see Table 5.7).

Table 5.7: ACO Commercial Performance on the ACO Core Measure Set – 90th Percentile

Measure Name	Nat'l 90th Pctl	Above 90th Percentile?						
		BVCHC	BROWN	INTEGRA	IHP	PCHC	PROSPECT	THUNDER-MIST
% of Measures Above Nat'l Benchmark		0%	78%	78%	33%	25%	63%	50%
Breast Cancer Screening	80%	No 68%	Yes 91%	Yes 89%	No 77%	No 71%	Yes 86%	No 76%
Child and Adolescent Well-Care Visits (Total)	74%	No 56%	Yes 83%	Yes 85%	No 73%	No 66%	No 73%	Yes 75%
Chlamydia Screening	57%	NR	Yes 73%	Yes 66%	No 51%	Yes 66%	Yes 63%	Yes 57%
Colorectal Cancer Screening	68%	No 55%	Yes 85%	Yes 81%	Yes 69%	No 53%	Yes 81%	No 66%
Controlling High Blood Pressure	75%	No 54%	No 74%	Yes 79%	No 73%	No 67%	Yes 83%	No 67%
Eye Exam for Patients with Diabetes	61%	No 35%	Yes 75%	Yes 65%	Yes 62%	No 59%	Yes 74%	Yes 68%
Follow-Up After Hospitalization for Mental Illness (7-Day)	64%	NR	No 63%	No 56%	No 47%	NR	No 55%	NR
Glycemic Status <8.0%	73%	No 37%	Yes 74%	No 70%	No 44%	No 58%	No 72%	No 59%
Immunizations for Adolescents (Combo 2)	41%	NR	Yes 64%	Yes 63%	Yes 45%	Yes 41%	NR	Yes 63%
Lead Screening in Children	NA	NR	85%	84%	NR	NR	NR	NR

Source: OHIC analysis of quality performance data submitted by commercial insurers in Rhode Island.

Note:

NA = Not Available.

NR = Not Reported. The ACO/AE did not meet the minimum denominator size required for public reporting.

AE Medicaid Performance on the ACO Core Measure Set – 75th Percentile

There was substantial variation in AE performance in the Medicaid market relative to the national 75th percentile.

- Brown University Health and Integra performed strongest overall, exceeding the 75th percentile for nearly all reported measures, while Prospect also exceeded the benchmark for a majority of measures.
- PCHC demonstrated moderate performance, exceeding the 75th percentile for several measures.
- BVCHC, IHP, and Thundermist exceeded the benchmark for relatively few measures.

As with the commercial population, non-FQHC-based provider organizations demonstrated superior performance to that of FQHCs. Here again, OHIC cannot determine if this difference reflects a) better care, b) better quality measurement or improvement processes, and/or c) differences in the social and health risks of patient populations.

Across AEs, performance most consistently exceeded the 75th percentile for *Eye Exam for Patients with Diabetes* and *Follow-Up After Hospitalization for Mental Illness (7-Day)*, while only Brown exceeded the benchmark for *Glycemic Status <8.0%* (see Table 5.8).

Table 5.8: AE Medicaid Performance on the ACO Core Measure Set – 75th Percentile

Measure Name	Nat'l 75th Pctl	Above 75th Percentile?						
		BVCHC	BROWN	INTEGRA	IHP	PCHC	PROSPECT	THUNDER-MIST
% of Measures Above Nat'l Benchmark		20%	100%	90%	10%	50%	70%	10%
Breast Cancer Screening	61%	No 57%	Yes 71%	Yes 67%	No 56%	Yes 70%	Yes 63%	No 56%
Child and Adolescent Well-Care Visits (Total)	61%	No 54%	Yes 69%	Yes 73%	No 57%	No 58%	Yes 62%	Yes 65%
Chlamydia Screening	65%	No 63%	Yes 66%	Yes 72%	No 50%	Yes 65%	No 63%	No 62%
Colorectal Cancer Screening	48%	Yes 49%	Yes 63%	Yes 53%	No 46%	Yes 51%	Yes 55%	No 46%
Controlling High Blood Pressure	71%	No 68%	Yes 77%	Yes 75%	No 69%	No 68%	Yes 74%	No 68%
Eye Exam for Patients with Diabetes	63%	Yes 67%	Yes 65%	Yes 67%	No 61%	Yes 72%	Yes 64%	Yes 68%
Follow-Up After Hospitalization for Mental Illness (7-Day)	49%	No 45%	Yes 68%	Yes 58%	Yes 55%	No 46%	Yes 50%	Yes 53%
Glycemic Status <8.0%	65%	No 51%	Yes 67%	No 58%	No 60%	No 60%	No 60%	No 59%
Immunizations for Adolescents (Combo 2)	44%	No 36%	Yes 45%	Yes 54%	No 35%	No 41%	Yes 56%	Yes 55%
Lead Screening in Children	76%	No 75.9%	Yes 91%	Yes 77%	No 70%	Yes 83%	No 69%	No 69%

Source: OHIC analysis of quality performance data of Rhode Island Accountable Entities submitted by Rhode Island managed care plans to EOHHS and provided to OHIC by EOHHS.

AE Medicaid Performance on the ACO Core Measure Set – 90th Percentile

- Brown University Health exceeded the 90th percentile for a majority of measures, including *Breast Cancer Screening*, *Child and Adolescent Well-Care Visits (Total)*, *Colorectal Cancer Screening*, *Controlling High Blood Pressure*, *Follow-Up After Hospitalization for Mental Illness (7-Day)*, and *Lead Screening in Children*.
- Integra also achieved 90th percentile performance on several measures, including *Breast Cancer Screening*, *Child and Adolescent Well-Care Visits (Total)*, *Chlamydia Screening*, and *Follow-Up After Hospitalization for Mental Illness (7-Day)*.
- Prospect and PCHC exceeded the 90th percentile for select measures, while Thundermist did so for one measure.
- BVCHC and IHP did not exceed the 90th percentile for any reported measure.

No AE exceeded the 90th percentile for Glycemic Status <8.0%. (see Table 5.9).

Table 5.9: AE Medicaid Performance on the ACO Core Measure Set – 90th Percentile

Measure Name	Nat'l 90th Pctl	Above 90th Percentile?						
		BVCHC	BROWN	INTEGRA	IHP	PCHC	PROSPECT	THUNDER-MIST
% of Measures Above Nat'l Benchmark		0%	60%	60%	0%	20%	20%	10%
Breast Cancer Screening	66%	No 57%	Yes 71%	Yes 67%	No 56%	Yes 70%	No 63%	No 56%
Child and Adolescent Well-Care Visits (Total)	68%	No 54%	Yes 69%	Yes 73%	No 57%	No 58%	No 62%	No 65%
Chlamydia Screening	71%	No 63%	No 66%	Yes 72%	No 50%	No 65%	No 63%	No 62%
Colorectal Cancer Screening	53%	No 49%	Yes 63%	No 52.6%	No 46%	No 51%	Yes 55%	No 46%
Controlling High Blood Pressure	75%	No 68%	Yes 77%	Yes 75%	No 69%	No 68%	No 74%	No 68%
Eye Exam for Patients with Diabetes	69%	No 67%	No 65%	No 67%	No 61%	Yes 72%	No 64%	No 68%
Follow-Up After Hospitalization for Mental Illness (7-Day)	58%	No 45%	Yes 68%	Yes 58%	No 55%	No 46%	No 50%	No 53%
Glycemic Status <8.0%	67%	No 51%	No 66.8%	No 58%	No 60%	No 60%	No 60%	No 59%
Immunizations for Adolescents (Combo 2)	52%	No 36%	No 45%	Yes 54%	No 35%	No 41%	Yes 56%	Yes 55%
Lead Screening in Children	83%	No 76%	Yes 91%	No 77%	No 70%	No 82.5%	No 69%	No 69%

Source: OHIC analysis of quality performance data of Rhode Island Accountable Entities submitted by Rhode Island managed care plans to EOHHS and provided to OHIC by EOHHS.